Table of Contents
TERIPARATIDE (r-hPTH 1-34)
Teriparatide
Teriparatide
Principal outcomes
PRECLINICAL DEVELOPMENT PROGRAM
Clinical (Phase 1-2) Studies
GHAC: Effects of teriparatide in the Treatment of Postmenopausal Women with Osteoporosis
GHAC PRIMARY ENDPOINT RESULTS Proportion of patients with 1 or more new vertebral fractures
Other Vertebral Fracture Results (not pre-specified)
Secondary endpoint: New Non-vertebral Atraumatic Fractures Combined
Study GHAC Non-vertebral Fractures by Site
GHAC: other secondary efficacy endpoints
GHAJ: Effects of teriparatide in the treatment of men with primary osteoporosis and osteoporosis associated with primary hypogonadism
GHAJ Treatment Exposure
GHAJ Results
Teriparatide: Clinical Efficacy Summary
Teriparatide: Clinical Efficacy Summary
OSTEOSARCOMA
OSTEOSARCOMA
Osteosarcoma
Osteosarcoma
Osteosarcoma
Osteosarcoma
Osteosarcoma
Osteosarcoma
Osteosarcoma
Teriparatide
|